Zyversa Therapeutics enters $1.4M ATM equity offering with A.G.P.

ZyVersa Therapeutics, Inc.

Entered ATM Agreement with A.G.P./Alliance Global Partners to sell up to $1,397,396 of common stock.
Agent receives 3.0% commission; sales at prevailing market prices under effective shelf registration.
Proceeds to be used for working capital and general corporate purposes, including R&D.
No minimum offering; Company not obligated to sell any shares under the Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.